TY - JOUR
T1 - Structure-activity relationships of sarafotoxins
T2 - chemical syntheses of chimera peptides of sarafotoxins S6b and S6c
AU - Takasaki, Chikahisa
AU - Aimoto, Saburo
AU - Kitazumi, Kazuhiro
AU - Tasaka, Kenji
AU - Shiba, Toshiharu
AU - Nishiki, Katsuyuki
AU - Furukawa, Yasuo
AU - Takayanagi, Ryoichi
AU - Ohnaka, Keizo
AU - Nawata, Hajime
PY - 1991/6/6
Y1 - 1991/6/6
N2 - The three chimera peptides of sarafotoxins S6b (SRTb) and S6c (SRTc), [Thr2SRTb, [Asn4]SRTb and [Glu9]SRTb, were synthesized chemically. From the comparisons of lethality, vasoconstrictor activity and receptor binding activity of SRTb, SRTa ([Asn13]SRTb), SRTc ([Thr2Asn4Glu9Asn13]SRTb), [Thr2SRTb, [Asn4]SRTb and [Glu9SRTb, it appears that the Lys9 to Glu9 substitution greatly diminishes these activities while the Lys4 to Asn4 substitution does not affect them, and the Ser2 to Thr2 substitution or the Tyr13 to Asn13 substitution slightly diminishes these activities. There results suggest that the very low activities of SRTc are caused mainly by the Lys9 to Glu9 substitution, but not by the Ser2 to Thr2 substitution, which was suggested to be responsible for the weak bioactivities of SRTd ([Thr2,Ile19]SRTb).
AB - The three chimera peptides of sarafotoxins S6b (SRTb) and S6c (SRTc), [Thr2SRTb, [Asn4]SRTb and [Glu9]SRTb, were synthesized chemically. From the comparisons of lethality, vasoconstrictor activity and receptor binding activity of SRTb, SRTa ([Asn13]SRTb), SRTc ([Thr2Asn4Glu9Asn13]SRTb), [Thr2SRTb, [Asn4]SRTb and [Glu9SRTb, it appears that the Lys9 to Glu9 substitution greatly diminishes these activities while the Lys4 to Asn4 substitution does not affect them, and the Ser2 to Thr2 substitution or the Tyr13 to Asn13 substitution slightly diminishes these activities. There results suggest that the very low activities of SRTc are caused mainly by the Lys9 to Glu9 substitution, but not by the Ser2 to Thr2 substitution, which was suggested to be responsible for the weak bioactivities of SRTd ([Thr2,Ile19]SRTb).
UR - http://www.scopus.com/inward/record.url?scp=0025852045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025852045&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(91)90616-X
DO - 10.1016/0014-2999(91)90616-X
M3 - Article
C2 - 1650701
AN - SCOPUS:0025852045
SN - 0014-2999
VL - 198
SP - 165
EP - 169
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 2-3
ER -